Mobilion Systems, Inc. in Chadds Ford is developing instruments that can identify molecules for diagnosing and treating diseases, writes John George for the Philadelphia Business Journal.

The life sciences company has raised $15.4 million in series A financing. It plans to use the funds to advance the development of its patented ion mobility separations technology.

The technology provides a clearer picture of molecules in compounds by identifying biomarkers linked to various diseases.

Mass spectrometry now used to identify molecules can’t always tell the difference between various compounds in a sample.

The ion mobility device that Mobilion is developing separates ionized compounds by size and shape.

“What we do is make instruments that see molecules that other instruments can’t identify,” explained CEO Melissa Sherman.

For now, Sherman said drug development companies can come into Mobilion’s research labs and use a beta version of the technology.

Mobilion’s plan is to introduce a beta version of its device in the field for early adopters during the first quarter of 2020.

Then, based on the feedback it receives, the company expects to launch a fully validated commercial product for research use in drug development in early 2021.

Read more about Mobilion Systems work here.

[uam_ad id=”62465″]